ライフサイエンスコーパス: decompensated heart failure

1 (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure).

2 ARRESS-HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure).

3 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

4 lity may benefit patients admitted for acute decompensated heart failure.

5 l and a key measure of treatment efficacy in decompensated heart failure.

6 ients hospitalized with a diagnosis of acute decompensated heart failure.

7 gestion, and outcomes in patients with acute decompensated heart failure.

8 tes acute respiratory distress syndrome from decompensated heart failure.

9 g sustained decongestion during treatment of decompensated heart failure.

10 dia (VT) in hospitalized patients with acute decompensated heart failure.

11 dent cohort of 75 subjects treated for acute decompensated heart failure.

12 apy for the treatment of patients with acute decompensated heart failure.

13 ening renal function during the treatment of decompensated heart failure.

14 e, was approved for the treatment of acutely decompensated heart failure.

15 idate drug in clinical trials to treat acute decompensated heart failure.

16 ated patients sometimes present acutely with decompensated heart failure.

17 rapy (CRT) in patients admitted for advanced decompensated heart failure.

18 iming of diuretics among patients with acute decompensated heart failure.

19 cting PCWP in patients admitted for advanced decompensated heart failure.

20 ents (80.5%) who were hospitalized for acute decompensated heart failure.

21 164 individuals (99% men) hospitalized with decompensated heart failure.

22 e events in hospitalized patients with acute decompensated heart failure.

23 that impair glucose transport induce acute, decompensated heart failure.

24 des (proBNP) in patients admitted with acute decompensated heart failure.

25 and quality of care for patients with acute decompensated heart failure.

26 act on renal function in patients with acute decompensated heart failure.

27 ransition from stable cardiac hypertrophy to decompensated heart failure.

28 serve as a marker for the severity of acute decompensated heart failure.

29 efficacy of UF versus standard care in acute decompensated heart failure.

30 er current investigation in the treatment of decompensated heart failure.

31 ategies for treatment of patients with acute decompensated heart failure.

32 rGLP-1 may be a useful metabolic adjuvant in decompensated heart failure.

33 shown to be efficacious in the treatment of decompensated heart failure.

34 s predict outcomes of patients admitted with decompensated heart failure.

35 ent in hemodynamic function in patients with decompensated heart failure.

36 n the short-term management of patients with decompensated heart failure.

37 calcium-sensitizing agent, in patients with decompensated heart failure.

38 he progression of compensated hypertrophy to decompensated heart failure.

39 ecting renal function in patients with acute decompensated heart failure.

40 used to guide diuretic therapy during acute decompensated heart failure.

41 ains a primary target of therapy for acutely decompensated heart failure.

42 within 12 hours of hospitalization for acute decompensated heart failure.

43 console, to improve decongestion in acutely decompensated heart failure.

44 se (COPD) exacerbation, pneumonia, and acute decompensated heart failure.

45 ach to the diagnosis and management of acute decompensated heart failure.

46 onse to acetazolamide in patients with acute decompensated heart failure.

47 ARDIA system to reduce congestion in acutely decompensated heart failure.

48 xtracorporeal membrane oxygenation for acute decompensated heart failure.

49 ean 7.3 years for development of incident or decompensated heart failure.

50 chaemia-reperfusion, cardiac hypertrophy and decompensated heart failure.

51 improve the outcomes of patients with acute decompensated heart failure.

52 reserved ejection fraction, as well as acute decompensated heart failure.

53 halting the progression from compensated to decompensated heart failure.

54 presenting with cardiogenic shock, and acute decompensated heart failure.

55 frequent cause for hospitalization in acute decompensated heart failure.

56 heart failure sometimes present acutely with decompensated heart failure.

57 ide on renal function in patients with acute decompensated heart failure.

58 nostic factors in patients hospitalized with decompensated heart failure.

59 affect renal function in patients with acute decompensated heart failure.

60 f 487 patients aged >/=75 years admitted for decompensated heart failure.

61 post hoc analysis for recurrent episodes of decompensated heart failure (0.37; 0.15-0.93) and cardio

62 xtracorporeal membrane oxygenation for acute decompensated heart failure, 1-year survival was 42%, bu

63 The most common initial diagnoses were acute decompensated heart failure (113 patients [45.5%]), pneu

64 ortality in patients hospitalized with acute decompensated heart failure: 4 HF-specific mortality pre

65 4 patients with CS, the majority were due to decompensated heart failure (50%) or myocardial infarcti

66 of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patients hospitalize

67 In patients with acute decompensated heart failure, a positive cardiac troponin

68 Acute decompensated heart failure accounts for more than 1 mil

69 tions associated with circulating LPS (e.g., decompensated heart failure, acute and chronic infection

70 ty is common among older patients with acute decompensated heart failure (ADHF) and is associated wit

71 nitroprusside (SNP) for patients with acute decompensated heart failure (ADHF) and low-output states

72 is and renal function in patients with acute decompensated heart failure (ADHF) and renal impairment

73 de (iBNP) and early intervention for acutely decompensated heart failure (ADHF) and whether these var

74 Acute decompensated heart failure (ADHF) can be complicated by

75 e vs standard SBP lowering on rates of acute decompensated heart failure (ADHF) events and death and

76 Trial), intensive BP treatment reduced acute decompensated heart failure (ADHF) events.

77 M) code criteria, do not differentiate acute decompensated heart failure (ADHF) from chronic stable H

78 Estimates of the numbers and rates of acute decompensated heart failure (ADHF) hospitalization are c

79 Acute decompensated heart failure (ADHF) is a highly morbid co

80 Acute decompensated heart failure (ADHF) is one of the leading

81 mechanism; however, its importance in acute decompensated heart failure (ADHF) is unknown.

82 Acute decompensated heart failure (ADHF) requiring hospitaliza

83 Background: Acute decompensated heart failure (ADHF) requiring hospitaliza

84 Acute decompensated heart failure (ADHF) was a frequent common

85 valsartan in patients hospitalized for acute decompensated heart failure (ADHF) was well-tolerated an

86 ure), 7,141 patients hospitalized with acute decompensated heart failure (ADHF) were randomized to re

87 in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving pa

88 vo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and sign

89 d volume overload are the hallmarks of acute decompensated heart failure (ADHF), and loop diuretics h

90 metabolic phenotypes of patients with acute decompensated heart failure (ADHF), patients with chroni

91 For patients hospitalized with acute decompensated heart failure (ADHF), the presence of kidn

92 ute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most

93 h acute cardiac illness, most commonly acute decompensated heart failure (ADHF).

94 with improvement in renal function in acute decompensated heart failure (ADHF).

95 receptor-like 1, identifies risk in acutely decompensated heart failure (ADHF).

96 prognostic factor for patients with acutely decompensated heart failure (ADHF).

97 tazolamide facilitates decongestion in acute decompensated heart failure (ADHF).

98 nd outcomes of aortic stenosis (AS) in acute decompensated heart failure (ADHF).

99 acetazolamide improved decongestion in acute decompensated heart failure (ADHF).

100 on and death after hospitalization for acute decompensated heart failure (ADHF).

101 of CS among children hospitalized for acute decompensated heart failure (ADHF).

102 ently poses a therapeutic challenge in acute decompensated heart failure (ADHF).

103 ined tachyarrhythmia (atrial/ventricular) or decompensated heart failure admission/transplantation/de

104 admission to discharge in consecutive acute decompensated heart failure admissions (n=656).

105 Most acute decompensated heart failure admissions are driven by con

106 emoglobin in patients hospitalized for acute decompensated heart failure (AHF).

107 ning renal function, is also common in acute decompensated heart failure, although the definition of

108 s, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) u

109 der patients who were hospitalized for acute decompensated heart failure, an early, transitional, tai

110 ommon cardiogenic shock causes such as acute decompensated heart failure and acute myocardial infarct

111 al function during hospitalization for acute decompensated heart failure and associated outcomes.

112 ide on renal function in patients with acute decompensated heart failure and baseline renal dysfuncti

113 Consecutive patients with acute decompensated heart failure and baseline renal dysfuncti

114 HF) trials during hospitalization with acute decompensated heart failure and clinical congestion.

115 is a primary therapeutic objective in acute decompensated heart failure and commonly monitored with

116 tal of 40 consecutive patients with advanced decompensated heart failure and CRT implanted >3 months,

117 Ritonavir and lopinavir precipitated acute, decompensated heart failure and death from pulmonary ede

118 intravenous (IV) diuretics in patients with decompensated heart failure and diuretic resistance resu

119 In acutely decompensated heart failure and heart failure with prese

120 n for hospitalization in patients with acute decompensated heart failure and is an important target f

121 Failure) that randomized patients with acute decompensated heart failure and preexisting WRF to inten

122 tal practice patterns of NIPPV use for acute decompensated heart failure and their relationship with

123 e therapeutic option for patients with acute decompensated heart failure and tissue hypoperfusion.

124 d arginine metabolism in patients with acute decompensated heart failure and to explore possible mech

125 s admitted to a single institution for acute decompensated heart failure and treated with UF: HFLEF (

126 fylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Asses

127 fylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Asses

128 fylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Asses

129 fylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Asses

130 nificantly associated with increased risk of decompensated heart failure and/or development of clinic

131 ic Optimization Strategy Evaluation in Acute Decompensated Heart Failure), and CARRESS-HF (Cardiorena

132 There were 17 CV events (12%, 6 CV deaths, 6 decompensated heart failure, and 5 arrhythmias; median t

133 ular events were a composite of arrhythmias, decompensated heart failure, and CV death.

134 infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascul

135 neous nature of patients admitted with acute decompensated heart failure, and the limitations of the

136 of hypotension while hospitalized with acute decompensated heart failure are not well understood.

137 using loop diuretics in patients with acute decompensated heart failure are often limited by the dev

138 ity outcomes for patients admitted for acute decompensated heart failure are poor and have not signif

139 tors when initiated soon after an episode of decompensated heart failure are unknown.

140 e transition from compensated hypertrophy to decompensated heart failure as a result of reduced phosp

141 e a context for Acute Study of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, we design

142 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), we assessed fac

143 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure [ASCEND-HF]; NCT00475852).

144 ion fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United S

145 d all consecutive patients hospitalized with decompensated heart failure at Mayo Clinic Hospitals in

146 , and unplanned clinic visits to treat acute decompensated heart failure based on the blinded adjudic

147 We analyzed hospitalizations for acute decompensated heart failure between October 2001 and Jan

148 patients (acute myocardial infarction, acute decompensated heart failure, biventricular failure, and

149 in the management of low output syndrome and decompensated heart failure but their effect on mortalit

150 component of therapy for patients with acute decompensated heart failure, but there are few prospecti

151 should be considered for patients with acute decompensated heart failure, but timing of implantation

152 E-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trials during h

153 olled trial, we assigned patients with acute decompensated heart failure, clinical signs of volume ov

154 Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic S

155 ty of ultrafiltration in patients with acute decompensated heart failure complicated by persistent co

156 an overview of the pathophysiology of acute decompensated heart failure, current management strategi

157 f the pathophysiologic derangements in acute decompensated heart failure, denoted by the acronym DRI(

158 ic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal R

159 y improves cardiac function in patients with decompensated heart failure due to severe left ventricul

160 In patients with decompensated heart failure due to volume overload, a tr

161 ospective consecutive patients with advanced decompensated heart failure (ejection fraction < or =30%

162 ventricular overload, dysfunction, frequent decompensated heart failure episodes, and excess mortali

163 When conventional therapy for acute decompensated heart failure fails, mechanical fluid remo

164 e, hemoconcentration during the treatment of decompensated heart failure has been associated with red

165 anagement strategy for patients with acutely decompensated heart failure has been limited to the use

166 lder patients who are hospitalized for acute decompensated heart failure have high rates of physical

167 progression from compensated hypertrophy to decompensated heart failure have not been thoroughly def

168 enic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfer

169 rtan (S/V) in stabilized patients with acute decompensated heart failure (HF) and reduced ejection fr

170 Currently, therapeutic options for decompensated heart failure (HF) are limited.

171 effect of tezosentan in patients with acute decompensated heart failure (HF) associated with acute c

172 -type natriuretic peptide) in the therapy of decompensated heart failure (HF) by assessing the hemody

173 Untreated edematous decompensated heart failure (HF) is associated with a si

174 ht to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory pro

175 ltrafiltration (SCUF) in patients with acute decompensated heart failure (HF) refractory to intensive

176 Recurrent episodes of decompensated heart failure (HF) represent an emerging c

177 outcomes of patients hospitalized for acute decompensated heart failure (HF) with preserved systolic

178 stabilized during hospitalization for acute decompensated heart failure (HF), initiation of sacubitr

179 designed to normalize loading conditions in decompensated heart failure (HF), reduces neurohormonal

180 In decompensated heart failure (HF), tolvaptan, a vasopress

181 ction in patients hospitalized with advanced decompensated heart failure (HF).

182 predictive of in-hospital mortality in acute decompensated heart failure (HF).

183 fraction, yet is often not primarily due to decompensated heart failure (HF).

184 tion of chronic oral medication during acute decompensated heart failure hospitalization may not be a

185 xtracorporeal membrane oxygenation for acute decompensated heart failure (i.e., cardiogenic shock com

186 xtracorporeal membrane oxygenation for acute decompensated heart failure in our ICU (67% of them had

187 prevents the transition from compensated to decompensated heart failure in part via upregulation of

188 technology for inpatient management of acute decompensated heart failure in patients with volume over

189 mass spectrometry in subjects with advanced decompensated heart failure in the intensive care unit (

190 We examined hospitalizations for acute decompensated heart failure in this database from 2005 t

191 Following treatment for acute decompensated heart failure, in-hospital observation on

192 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) included 4205 patients hosp

193 association between air pollution and acute decompensated heart failure including hospitalisation an

194 outcome of hospitalization for management of decompensated heart failure, initiation of mechanical ci

195 Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial.

196 Acute decompensated heart failure is a medical emergency and r

197 Hypotension while hospitalized for acute decompensated heart failure is an independent risk facto

198 Improvement in renal function (IRF) in acute decompensated heart failure is associated with adverse o

199 The mainstay of treatment of acute decompensated heart failure is diuretic therapy.

200 SBP reduction) during the treatment of acute decompensated heart failure is strongly and independentl

201 te coronary syndromes, but its role in acute decompensated heart failure is unclear.

202 stable heart failure but their role in acute decompensated heart failure is unclear.

203 mong patients who are hospitalized for acute decompensated heart failure is unknown.

204 not improve renal function in patients with decompensated heart failure, mild chronic renal insuffic

205 Acute decompensated heart failure modifies the course of chron

206 Patients >=60 years old admitted for acute decompensated heart failure (n=349) were randomized to e

207 The Acute Decompensated Heart Failure National Registry (ADHERE) a

208 rom >100,000 hospitalizations from the Acute Decompensated Heart Failure National Registry (ADHERE) d

209 h heart failure without CRT-D from the Acute Decompensated Heart Failure National Registry (ADHERE) h

210 of observational patient data from the Acute Decompensated Heart Failure National Registry (ADHERE),

211 January 2004 that were recorded in the Acute Decompensated Heart Failure National Registry (ADHERE).

212 Patients from ADHERE (Acute Decompensated Heart Failure National Registry) who were

213 talization episodes entered in ADHERE (Acute Decompensated Heart Failure National Registry).

214 re National Registry-United States and Acute Decompensated Heart Failure National Registry-Internatio

215 re National Registry-United States and Acute Decompensated Heart Failure National Registry-Internatio

216 amined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-United Sta

217 Among both Acute Decompensated Heart Failure National Registry-United Sta

218 ped from 3 clinical databases (ADHERE [Acute Decompensated Heart Failure National Registry], EFFECT s

219 iveness of Nesiritide in Patients With Acute Decompensated Heart Failure; NCT00475852).

220 Treatment of decompensated heart failure often includes administratio

221 s > or =50 years of age who met criteria for decompensated heart failure on hospital admission.

222 In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i like

223 Clinical manifestations ranged from decompensated heart failure or sudden death in those pre

224 Presenting symptoms when present were decompensated heart failure or sudden death.

225 l arrhythmias in this population can lead to decompensated heart failure or thromboembolism and thera

226 ther acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascula

227 alization for myocardial infarction, stroke, decompensated heart failure, or urgent revascularization

228 ion rates, morbidity, and mortality of acute decompensated heart failure, other newer approaches, suc

229 arginine metabolism was observed in advanced decompensated heart failure, particularly with pulmonary

230 gen/creatinine ratio (BUN/Cr) could identify decompensated heart failure patients likely to experienc

231 was then prospectively validated in 50 acute decompensated heart failure patients using meticulously

232 is population with outcomes similar to acute decompensated heart failure patients with low left ventr

233 ip between intensive volume removal in acute decompensated heart failure patients with preexisting wo

234 Conclusions In acute decompensated heart failure patients with preexisting WR

235 an treatment inhibits MPO release by PMNs in decompensated heart failure patients.

236 with greater iBNP levels (Registry for Acute Decompensated Heart Failure Patients; NCT00366639).

237 In patients being treated for acute decompensated heart failure, poor natriuretic response c

238 Acute decompensated heart failure presents a challenging thera

239 orsening of their condition, including acute decompensated heart failure, quality of life deteriorate

240 In older patients hospitalized for acute decompensated heart failure, quality of life improves in

241 Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmis

242 Acute decompensated heart failure refers to the worsening of s

243 fer between myocardial infarction- and acute decompensated heart failure-related hypoperfusion, encom

244 Acute decompensated heart failure remains the most common caus

245 Acute decompensated heart failure represents a major, growing

246 daily to standard medical treatment of acute decompensated heart failure resulted in a 25% increase i

247 loop diuretic therapy in patients with acute decompensated heart failure resulted in a greater incide

248 itide is approved for the treatment of acute decompensated heart failure, retrospective analyses have

249 least 40 years and hospitalization for acute decompensated heart failure, severe systemic infection w

250 1.13 [0.92 to 1.37], p = 0.002) in advanced decompensated heart failure subjects.

251 r arrhythmias in this population can lead to decompensated heart failure, syncope, and sudden cardiac

252 The acute decompensated heart failure syndrome is characterized by

253 ement of our understanding and management of decompensated heart failure syndromes but for the transl

254 s has not been matched by similar success in decompensated heart failure syndromes.

255 k period during which interventions to avert decompensated heart failure that necessitates hospitaliz

256 -HF trial (Cardiorenal Rescue Study in Acute Decompensated Heart Failure) that randomized patients wi

257 ion fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitri

258 Among patients with acute decompensated heart failure, there were no significant d

259 f age, she was admitted to our hospital with decompensated heart failure to be evaluated for a heart

260 dy, we randomly assigned patients with acute decompensated heart failure to empagliflozin 25 mg daily

261 d trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide admini

262 ars or older who were hospitalized for acute decompensated heart failure to rehabilitation interventi

263 rt study of 218 patients admitted with acute decompensated heart failure to the Nashville VA Medical

264 oral neurohormonal antagonists during acute decompensated heart failure treatment negatively influen

265 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial.

266 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hosp

267 ause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients r

268 ventilation (NIPPV) for patients with acute decompensated heart failure was introduced almost 20 yea

269 IRF during decongestive therapy for acute decompensated heart failure was not associated with impr

270 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was a global randomized tri

271 Pressure Measurements in Patients With Acute Decompensated Heart Failure) was a single-center prospec

272 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was used to perform genome-

273 feasibility trial, 30 patients with acutely decompensated heart failure were assigned to preCARDIA t

274 ents hospitalized for the treatment of acute decompensated heart failure will experience significant

275 Finally, acute decompensated heart failure with hypoperfusion may frequ

276 ients >/=55 years of age admitted with acute decompensated heart failure with preserved ejection frac

277 Decompensated heart failure with reduced ejection fracti

278 (Acetazolamide in Decompensated Heart Failure with Volume Overload [ADVOR]

279 Patients from the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial

280 decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.

281 ients from the ADVOR trial (Acetazolamide in Decompensated Heart Failure With Volume Overload), rando

282 d faster decongestion in patients with acute decompensated heart failure with volume overload, is unc

283 mong hospitals in the use of NIPPV for acute decompensated heart failure without evidence for differe

284 al involving patients hospitalized for acute decompensated heart failure, worsened renal function, an

285 assigned a total of 188 patients with acute decompensated heart failure, worsened renal function, an